← All indications
Choroideremia
An X chromosome-linked abnormality characterized by atrophy of the choroid and degeneration of the retinal pigment epithelium causing night blindness.
Drugs by status
Phase 3 trials (1)
Phase 2 trials (4)
Other trials (1)
Organizations
Organization Involved with Phase 3 Indications (1)
Organization Involved with Phase 2 Indications (16)
- Spark Therapeutics
- University of Pennsylvania
- University of London
- Harvard University
- STZ eyetrial
- University of Manchester
- University of Miami
- University of Alberta
- University of Oxford
- University of Tuebingen
- Moorgreen Hospital, Southampton
- Alberta Innovates Health Solutions
- Canadian Institutes of Health Research (CIHR)
- Canada Foundation for Innovation
- Choroideremia Research Foundation Canada
- Foundation Fighting Blindness
Organization Involved with Phase 1 Indications (2)